Effect of Metformin on Biomarkers of Colorectal Tumor Cell Growth

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Colorectal Neoplasms

In brief

The purpose of this study is to investigate the effects of short term oral Metformin therapy on biomarkers for tumor growth in subjects with newly diagnosed colon or rectal adenocarcinoma. It is hypothesized that there are independent actions of Metformin on the outcome of subjects with colorectal cancer (CRC). Also hypothesized is that metformin effects on CRC cell growth will correlate with this drug's effects on markers mentioned above, because the markers are closely related to tumor growth and metastases.

Key facts

Study ID
NCT01632020
Run by
University of Arkansas
People needed
7
Starts
2012-08-01
Expected to finish
2015-01-01
Last updated by the study team
2016-07-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.